MODULATION OF SYNOVIAL FIBROBLAST PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR PRODUCTION BY PROTEIN-KINASE-C

被引:6
|
作者
UHL, J
NEWTON, RC
GROSS, JL
ROMMI, W
MOCHAN, E
机构
[1] DUPONT CO,DEPT MED PROD,GLENOLDEN,PA 19036
[2] UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT BIOCHEM,CAMDEN,NJ
[3] UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT FAMILY MED,CAMDEN,NJ
关键词
SYNOVIAL FIBROBLAST; PROTEIN KINASE-C; PLASMINOGEN ACTIVATOR INHIBITOR;
D O I
10.1016/0925-4439(91)90082-K
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phorbol myristate acetate (PMA) added to human synovial fibroblast cultures caused a dose-dependent increase in the production of plasminogen activator inhibitor-type 1 (PAI-1). In addition, PMA inhibited endogeneous and interleukin-1 (IL-1) induced plasminogen activator (PA) activity, while increasing mRNA PAI-1 levels. Other protein kinase C (PKC) activators, mezerein and teleocidin B4, caused similar effects. The simultaneous addition of the PKC antagonists, H-7 or staurosporine, prevented the inhibition of PA activity by PMA. This study shows that activation of PKC inhibits PA and stimulates PAI production in human synovial fibroblasts. These results suggest that activation of PKC may play an important role in regulating increased PA production associated with joint destruction in rheumatoid arthrits (RA).
引用
收藏
页码:283 / 288
页数:6
相关论文
共 50 条
  • [41] THROMBIN AND PLASMINOGEN-ACTIVATOR INHIBITOR - RESPONSE
    COLUCCI, M
    SEMERARO, N
    BLOOD, 1990, 76 (04) : 853 - 854
  • [42] FIBRINOLYTIC THERAPY - PLASMINOGEN-ACTIVATOR INHIBITOR
    HONIGL, K
    PILGER, E
    STARK, G
    BERTUCH, H
    VASA-JOURNAL OF VASCULAR DISEASES, 1988, : 103 - 106
  • [43] THE INFLUENCE OF SURGERY ON PLASMINOGEN-ACTIVATOR INHIBITOR
    NEERSTRAND, H
    HEDNER, U
    LUTZEN, O
    HAUCH, O
    JORGENSEN, LN
    NERSTROM, H
    KOLLE, TR
    WILLEJORGENSEN, P
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 557 - 557
  • [44] PLASMINOGEN-ACTIVATOR INHIBITOR IN ACUTE STROKE
    BROCKMANN, MJ
    SCHWENDEMANN, G
    STIEF, TW
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1991, 14 (02) : 143 - 150
  • [45] TISSUE PLASMINOGEN-ACTIVATOR INHIBITOR IN THE EPIDERMIS
    HASHIMOTO, K
    KATAYAMA, I
    NISHIOKA, K
    BRITISH JOURNAL OF DERMATOLOGY, 1985, 113 (05) : 523 - 527
  • [46] PLASMINOGEN-ACTIVATOR INHIBITOR IN PLASMA AND ARTERIOSCLEROSIS
    MATSUDA, T
    MORISHITA, E
    JOKAJI, H
    SAITO, M
    KUMABASHIRI, I
    AKAKURA, H
    UOTANI, C
    YAMAZAKI, M
    ATHEROSCLEROSIS III: RECENT ADVANCES IN ATHEROSCLEROSIS RESEARCH: THE THIRD SARATOGA INTERNATIONAL CONFERENCE ON ATHEROSCLEROSIS IN NEKOMA, 1995, 748 : 394 - 398
  • [47] INACTIVATION OF PLASMINOGEN-ACTIVATOR INHIBITOR BY OXIDANTS
    LAWRENCE, DA
    LOSKUTOFF, DJ
    BIOCHEMISTRY, 1986, 25 (21) : 6351 - 6355
  • [48] PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITY IN SEPTICEMIA
    PARAMO, JA
    CUESTA, B
    HERNANDEZ, M
    FERNANDEZ, J
    PALOMA, MJ
    ROCHA, E
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 513 - 513
  • [49] PRODUCTION OF PROTEASES TYPE PLASMINOGEN-ACTIVATOR AND THEIR INHIBITOR IN CORNEA
    MIRSHAHI, M
    MIRSHAHI, S
    SORIA, C
    SORIA, J
    THOMAIDIS, A
    POULIQUEN, Y
    FAURE, JP
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 160 (03) : 1021 - 1025
  • [50] PLASMINOGEN-ACTIVATOR INHIBITOR-1 IS THE PRIMARY INHIBITOR OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN PREGNANCY PLASMA
    JORGENSEN, M
    PHILIPS, M
    THORSEN, S
    SELMER, J
    ZEUTHEN, J
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (03) : 872 - 878